FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis
The sNDA submission was supported by data from the pivotal phase 3 HARMONY study.
Psychosis
Xanomeline-Trospium Bests Placebo in Decreasing PANSS Total Score
The goal for this phase 2 trial was to assess the efficacy and safety of the combination oral agent xanomeline-trospium in patients with acute exacerbations of schizophrenia.
Psychosis Treatments
A comparative dosing and titration chart of commonly used first-generation and second-generation antipsychotics.
Pharmacogenetic Considerations for Psychotropic Drugs
Dosing adjustments and precautions for pharmacogenetic variations with psychotropic medications.
Atypical Antipsychotic Pharmacokinetics
Chart Pharmacokinetics of Atypical Antipsychotics, including Bioavailability, Half-life and CYP 450 Metabolism.
Low Prevalence of Neuropsychiatric Lupus in Patients With Psychosis With Positive Antinuclear Antibodies
Researchers determined the prevalence of neuropsychiatric systemic lupus erythematosus in patients with psychosis with positive antinuclear antibodies.
FDA Committees Vote on Novel Therapy for Schizophrenia, Bipolar I Disorder
ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
Proteomic Expression Profiles May Allow for Risk Stratification for Psychotic Disorders or Psychotic Episodes
This study investigates whether proteomic biomarkers may aid in the prediction of the transition to psychotic disorder in the clinical high-risk state and adolescent psychotic experiences in the general population.
Psychosis Relapse Common During Assured Antipsychotic Treatment
Researchers conducted a systematic review and meta-analysis to assess the incidence and predictors of psychosis relapse in individuals receiving treatment with antipsychotic agents.
-
Loading...
-
Loading...
Next post in Schizophrenia and Psychoses
